In this interview we discuss results of the PlanB trial, which showed that use of the 21-gene recurrence score, Oncotype DX, can identify patients with early breast cancer who likely do not need chemotherapy.
Oleg Gluz, MD
Advertisement
Articles by Oleg Gluz, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma
2
Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC
3
What Are The Top Lymphoma Abstracts at ASCO 2026?
4
How the Landscape of GI Oncology is Evolving: A 2026 ASCO Preview
5